Benzylpenicillin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Benzylpenicillin: From Bacterial Infection to Pericoronitis
One-Sentence Summary
Benzylpenicillin is an injectable penicillin antibacterial, marketed in South Africa under 2 SAHPRA registrations. The TxGNN model predicts it may be effective for pericoronitis (score 99.36%), but this is a model prediction only, with 0 clinical trials and 0 publications for this pairing. Among the other predicted indications, recurrent aphthous stomatitis (canker sore) has the strongest support, including a 2020 randomized controlled trial of topical penicillin.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the supplied SAHPRA registration data (injectable antibacterial) |
| Predicted New Indication | Pericoronitis |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, benzylpenicillin is a penicillin-class antibacterial. Its efficacy in bacterial infections is established, and mechanistically it may be applicable to pericoronitis.
Pericoronitis is a polymicrobial infection of the gum around a partly erupted tooth, so an antibacterial is biologically plausible. Two factors weigh against it. Benzylpenicillin is given by injection and has a short half-life, which is a poor fit for a mostly local dental condition. No trials or literature support this specific drug-disease pairing.
Clinical Trial Evidence
Currently no related clinical trials registered. No SANCTR or PACTR identifiers were found.
Literature Evidence
Currently no related literature available.
Other Predicted Indications Worth Noting
The first-ranked prediction has no evidence. The table below shows the other predictions in the pack that have the most relevant evidence.
| Predicted Indication | TxGNN Score | Evidence Level | Decision Stage / Recommendation | Evidence Summary |
|---|---|---|---|---|
| Canker sore (recurrent aphthous stomatitis) | 99.27% | L2 | S2 / Research Question | A randomized double-blind trial of topical penicillin (PMID 33273940, 2020) and two penicillin G potassium troche studies (14676759, 2003; 20188604, 2010). Effect sizes were not visible in the input and need verification. The only registered trial (NCT02750800) is an adalimumab study and is irrelevant. |
| Ulcerative stomatitis | 99.26% | L4 | S1 / Hold | Only uncontrolled 1940s clinical reports and narrative reviews. No modern controlled evidence. |
| Conjunctivitis | 97.94% | L4 | S0 / Hold | General reviews and resistance literature only. No controlled benzylpenicillin study. |
| Chronic ethmoidal sinusitis | 97.63% | L4 | S0 / Hold | Studies concern other agents (amoxicillin-clavulanate, ciprofloxacin). Indirect at best. |
| Gingival recession | 99.31% | L4 | S0 / Hold | Studies test amoxicillin/metronidazole in periodontitis, not benzylpenicillin. Recession is an outcome measure, not an infection. |
| Denture stomatitis | 99.26% | L4 | S0 / Hold | Mainly Candida-associated, and penicillin has no antifungal activity. Only preclinical and indirect records. |
| Chemotherapy-induced oral mucositis, gingival leukoplakia, cat-scratch disease | 97.78–99.26% | L5 | S0 / Hold | Prediction only. No trials or literature, and no plausible mechanistic link. |
Note that the canker sore studies use topical penicillin G. This differs from the injectable products registered in South Africa.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. A/20.1.2/626 | Benzyl Penicillin Fresenius 1Mu | Injection | Not stated in supplied record |
| Reg. No. A/20.1.2/444 | Bio-Pen 1Mu | Injection | Not stated in supplied record |
Both registrations are injectable only. No topical or oral benzylpenicillin product appears in the supplied data. Essential Medicines List (EML) status was not included in the supplied data.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The pericoronitis prediction rests on the model score alone, and no trials or literature support it. The injectable-only South African registrations also limit how well this drug fits a dental indication.
To proceed, the following is needed:
- SAHPRA Professional Information (PI) for both registrations, to confirm approved indications, warnings and contraindications (this is a blocking gap for safety screening)
- Mechanism of action data (e.g. from DrugBank)
- Full-text review of the three topical penicillin G studies in recurrent aphthous stomatitis to verify outcomes. If they hold up, this is a better research question than pericoronitis.
- For any topical-use idea, a check on whether a suitable topical formulation exists in South Africa, since current registrations are injectable only
- Comparison against current guidelines for oral infections, where other agents are often preferred
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.